Coherus BioSciences, Inc. (CHRS)
- Previous Close
2.0000 - Open
2.0100 - Bid 2.0400 x 500
- Ask 2.0700 x 500
- Day's Range
1.9500 - 2.0900 - 52 Week Range
1.4300 - 8.3300 - Volume
2,879,742 - Avg. Volume
3,242,438 - Market Cap (intraday)
234.941M - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5300 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.43
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
www.coherus.comRecent News: CHRS
Performance Overview: CHRS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHRS
Valuation Measures
Market Cap
227.00M
Enterprise Value
590.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.73
Price/Book (mrq)
--
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
-3.04
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.48%
Return on Assets (ttm)
-21.75%
Return on Equity (ttm)
--
Revenue (ttm)
257.24M
Net Income Avi to Common (ttm)
-237.89M
Diluted EPS (ttm)
-2.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
117.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-70.1M
Research Analysis: CHRS
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: CHRS
CHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingBearishPrice TargetCHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetCHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetCHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice Target